Yan Fong Lam

Rentian Technology Holdings Ltd. is an investment company. It operates through the following segments: Human-Machine Interactive Devices (HMID), Internet-of-things Solution, Intelligent Documentation Service (IDS), and Investing. The Human-Machine Interactive Devices segment relates to the development of terminal hardware, software and services application for treasury and taxation, finance, education, and other key industries. The Internet-of-things Solution segment refers to cloud computing and data processing and analysis; telecommunication infrastructure and technologies; and terminal computing for corporate internet-of-things systems. The Intelligent Documentation Service segment provides specialized services to accelerate document-driven business processes. The Investing segment refers to investment in mid and small caps. The company was founded on September 10, 1998 and is headquartered in Hong Kong.

Lam & Co. is a Singaporean company that specializes in ice cream and frozen desserts. The private company is based in Singapore, Singapore. The company was founded by Philip Lam, who has been the CEO since incorporation.

Mingyuan Medicare Development Co. Ltd. engages in provision of medicare solutions for the early detection and prevention of diseases particularly in China. It operates through the following segments: Protein Chips, Healthcare, Medical Centers Management, Individualized Target Therapy, and Bio-Drugs. The Protein Chips segment manufactures and distributes C-12 products to hospitals, medical centers, and life insurance companies in China. The Healthcare segment engages in the provision of sales and marketing campaign for HPV DNA testing kits and making important progress to register products for distribution to female patients at hospitals nationwide. The Medical Centers Management segment engages in the provision of healthcare services for residents living in cities. The Individualized Target Therapy segment specializes in molecular diagnostic kits for leukemia, lymphoma and individualised target cancer therapy. The Bio-Drugs segment engages in the development, production and commercialization of a new generation of non-specific nanotechnology immunomodulatory drugs known as non-cell Corynebacterium pavum products. The company was founded on May 8, 1989 and is headquartered in Hong Kong.